Ruxolitinib hemifumarate is used as an oral Janus kinase (JAK1/JAK2) inhibitor to treat several serious hematologic and inflammatory conditions. Used to treat myelofibrosis (a rare bone marrow cancer). Indicated for polycythemia vera in patients intolerant to hydroxyurea. Approved for graft-versus-host disease (GVHD) after stem cell transplant. Investigated and sometimes used off-label for atopic dermatitis and alopecia areata. It is grouped under the following drug class(es): Antineoplastic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Jakafi, Jakavi and Opzelura. Its PubChem CID is 168449714.
Ruxolitinib hemifumarate
| CAS No | 2803478-47-7 |
|---|---|
| Molecular Formula | C38H40N12O4 |
| Molecular Weight | 728.8 g/mol |
| Synonyms | (E)-but-2-enedioic acid;(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Ruxolitinib hemifumarate is used as an oral Janus kinase (JAK1/JAK2) inhibitor to treat several serious hematologic and inflammatory conditions. Used to treat myelofibrosis (a rare bone marrow cancer).
The listed CAS number is 2803478-47-7.
The listed molecular formula is C38H40N12O4.
The listed molecular weight is 728.8 g/mol.
(E)-but-2-enedioic acid;(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile.
The source lists Jakafi, Jakavi and Opzelura.